Organon & Co. (OGN)
Health Care3 articles
Price chart
Organon & Co. (OGN) overview
Organon is a women’s-health-focused pharmaceutical company spun off from Merck. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Organon & Co. trades on the NYSE under the ticker symbol OGN. As of the most recent market data, the stock was priced around $13.76, up 0.00% on the session, giving Organon & Co. a market capitalization of roughly $3.61B.
Over the past 52 weeks, OGN has traded between $5.69 and $13.77. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 17.6, a common gauge of how richly the market prices the company's earnings. Organon & Co. also pays a dividend, currently yielding around 58.00%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch OGN
As one of the larger companies in the Health Care sector, Organon & Co. is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch OGN for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest OGN news
Organon & Co (OGN) Stock Reaches 52-Week High of 13.73 USD
Organon & Co (OGN) stock has reached a 52-week high of 13.73 USD. This milestone reflects investor confidence and could signal positive market trends for the company. The stock's performance may influence perceptions of the firm as a viable investment option. For investors, this achievement suggests potential upward momentum in the stock price.
Read More: Organon & Co (OGN) Stock Reaches 52-Week High of 13.73 USD
InvestingPro's Fair Value Indicates Organon 69% Gain Potential
InvestingPro's Fair Value model suggests that Organon (OGN) has a potential upside of 69%. This assessment is based on the company's current valuation relative to its estimated fair value. The findings highlight potential growth opportunities for investors. The model incorporates fundamental metrics and market trends that may influence Organon's stock performance in the near term. Understanding these figures is crucial for investors looking to make informed decisions regarding Organon.
Read More: InvestingPro's Fair Value Indicates Organon 69% Gain Potential
Organon (OGN) Surges 39% on $12 Billion Merger Speculation
Organon & Co. (OGN) experienced a significant increase of 38.8% week-on-week following reports of a potential $12 billion acquisition by Sun Pharmaceutical Industries. No official confirmation has been issued regarding the merger. Additionally, Organon reported a decreased net income of 78% to $187 million in 2024, with revenues down 3% to $6.2 billion. In the fourth quarter, the company recorded a net loss of $205 million, compared to a net income of $109 million the previous year, while quarterly revenues also declined by 5.3% to $1.5 billion.
Read More: Organon (OGN) Surges 39% on $12 Billion Merger SpeculationMore Health Care stocks
Frequently asked questions
Is Organon & Co. in the S&P 500?
Yes. Organon & Co. (OGN) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is OGN in?
Organon & Co. is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest OGN news?
This page collects recent Organon & Co. (OGN) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Organon & Co.'s stock price?
As of the most recent market data, Organon & Co. (OGN) traded at approximately $13.76. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is Organon & Co.'s market cap?
Organon & Co. has a market capitalization of roughly $3.61B, based on its most recent share price and shares outstanding.
What is OGN's P/E ratio?
OGN trades at a trailing price-to-earnings ratio of about 17.6. The P/E ratio compares a company's share price to its earnings per share.